Last reviewed · How we verify

Insulatard, flexpen

Göteborg University · FDA-approved active Small molecule

Insulatard is a long-acting insulin suspension that provides basal insulin coverage by slowly releasing insulin to maintain blood glucose control between meals and overnight.

Insulatard is a long-acting insulin suspension that provides basal insulin coverage by slowly releasing insulin to maintain blood glucose control between meals and overnight. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameInsulatard, flexpen
SponsorGöteborg University
Drug classLong-acting insulin (NPH insulin)
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulatard is a neutral protamine Hagedorn (NPH) insulin formulation, a suspension of insulin crystals complexed with protamine that delays absorption from the subcutaneous injection site. This extended-release profile allows for once or twice daily dosing to provide steady background insulin levels, mimicking the pancreas's basal insulin secretion. It is typically used in combination with rapid-acting insulins to achieve comprehensive glycemic control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: